A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

Vaishali Sanchorawala, Giovanni Palladini, Vishal Kukreti, Jeffrey A. Zonder, Adam D. Cohen, David C. Seldin, Angela Dispenzieri, Arnaud Jaccard, Stefan O. Schönland, Deborah Berg, Huyuan Yang, Neeraj Gupta, Ai Min Hui, Raymond L. Comenzo, Giampaolo Merlini

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis'. Together they form a unique fingerprint.

Chemical Compounds

Medicine & Life Sciences